Pivotal EB-101 Cell Therapy Trial Adds 2nd Site on Other US Coast

Pivotal EB-101 Cell Therapy Trial Adds 2nd Site on Other US Coast

301317

Pivotal EB-101 Cell Therapy Trial Adds 2nd Site on Other US Coast

The pivotal VIITAL study of EB-101, Abeona Therapeutics‘ experimental therapy for recessive dystrophic epidermolysis bullosa (RDEB), now has a second clinical site on the other U.S. coast — at the UMass Memorial Medical Center in Worcester, Massachusetts — the company announced. The first clinical site, where the Phase 3 trial is currently underway, is Stanford University Medical Center, in Palo Alto, California. Contact details for the Stanford site can be found here. “With UMass and Stanford, we…

You must be logged in to read/download the full post.